South Africa Visual Prosthesis Market Size & Outlook, 2025-2033
South Africa Visual Prosthesis Market Insights
- According to Reed Intelligence analysis, the South Africa Visual Prosthesis Market size was USD 3.71 Million in 2024 and is projected to reach USD 10.8 Million by 2033.
- The South Africa market is projected to grow at a CAGR of 12.39% between 2026 and 2033.
- By segment, Retina Implant Alpha AMS emerged as the largest By Product Type in terms of market size in 2024.
- Retina Implant Alpha AMS is anticipated to remain the most attractive By Product Type segment, recording the fastest growth during the forecast period.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- As of 2024, South Africa held 1.11% of the global Visual Prosthesis Market size.
- By 2033, United States is anticipated to capture the largest share of the global Visual Prosthesis Market.
- In Middle East and Africa, United Arab Emirates is expected to lead the regional Visual Prosthesis Market size by 2033.
- Saudi Arabia will remain the fastest-growing market in Middle East and Africa, reaching USD 12.94 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 3.71 Million |
| Market Size In 2033 | USD 10.8 Million |
| Largest segment | Retina Implant Alpha AMS |
| Units | Revenue in USD Million |
| CAGR | 12.39% (2025-2033) |
| Segmnetation Covered | |
| By Product Type |
|
| By Indication |
|
| By End-User |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
South Africa Visual Prosthesis Market By Product Type 2025-2033 (USD Million)
| By Product Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Retina Implant Alpha AMS | XX.x | XX.x | XX.x | 1.77 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Implantable Miniature Telescope | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Argus II | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
South Africa Visual Prosthesis Market By Indication 2025-2033 (USD Million)
| By Indication | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age-Related Macular Degeneration (AMD) | XX.x | XX.x | XX.x | 1.67 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Retinitis Pimentos (RP) | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Other Retinal Degenerative Diseases | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
South Africa Visual Prosthesis Market By End-User 2025-2033 (USD Million)
| By End-User | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Speciality eye clinics | XX.x | XX.x | XX.x | 1.49 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Eye hospitals | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Eye care centres | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
